Vaxcyte
PCVX
223 hedge funds and large institutions have $6.48B invested in Vaxcyte in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 87 increasing their positions, 68 reducing their positions, and 16 closing their positions.
236% more call options, than puts
Call options by funds: $9.9M | Put options by funds: $2.94M
131% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 16
28% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 68
25% more capital invested
Capital invested by funds: $5.17B → $6.48B (+$1.31B)
10% more funds holding
Funds holding: 202 → 223 (+21)
8% more funds holding in top 10
Funds holding in top 10: 13 → 14 (+1)
0.41% more ownership
Funds ownership: 108.02% → 108.43% (+0.41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$60M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$30.1M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$23.5M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$20M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MVM
Medicxi Ventures Management
St. Helier,
Jersey
|
-$53.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$32.3M |
| 3 |
FAM
Fred Alger Management
New York
|
-$22M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$18.1M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$17.1M |
PCVX Hedge Fund Activity: Q4 2023 in Review
223 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q4 2023, worth a combined $6.48B — up 25% from $5.17B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new PCVX positions and 16 closed out — a net gain of 21 holders — while 87 added to existing stakes and 68 trimmed.
The largest buyer was BlackRock, adding an estimated $60M. The largest seller was Medicxi Ventures Management, exiting entirely with an estimated $53.5M sold.
- 223 institutional investors held Vaxcyte (PCVX) as of Q4 2023, up from 202 in Q3 2023.
- Funds reported $6.48B of Vaxcyte stock for Q4 2023, up 25% quarter-over-quarter.
- 37 funds opened new Vaxcyte positions in Q4 2023 and 16 closed out, a net change of +21 holders.
- The largest Vaxcyte buyer in Q4 2023 was BlackRock, an estimated $60M added.
- The largest Vaxcyte seller in Q4 2023 was Medicxi Ventures Management, an estimated $53.5M sold.
Based on aggregated 13F filings for Q4 2023.